乌干达儿童无并发症恶性疟四种青蒿素联合疗法疗效随机试验
在乌干达三个地区开展随机开放标签4期试验,808名6月龄至10岁无并发症恶性疟患儿接受四种青蒿素联合疗法之一,随访42天。
要点
- 双氢青蒿素-哌喹和青蒿琥酯-阿莫地喹的PCR校正28天疗效达97%-100%。
核心结论
- 蒿甲醚-苯芴醇与其他受试联合疗法相比,与更高的疟疾复发风险相关。
- K13突变与寄生虫清除延迟相关。
- 应考虑因蒿甲醚-苯芴醇疗效欠佳而调整无并发症疟疾的一线治疗方案。
研究设计与样本
- 在乌干达Agago、Arua和Busia三个地区开展的随机、开放标签、4期临床试验。
- 纳入808名6月龄至10岁无并发症恶性疟患儿,随机分配接受四种青蒿素联合疗法之一,随访42天。
- 主要结局为显微镜评估的寄生虫血症,分析未校正和PCR校正的适宜临床和寄生虫学应答。
主要发现
- 所有方案耐受良好,最常见不良事件为上呼吸道感染、腹泻和贫血,无不良事件归因于研究药物。
临床怎么用
- 在乌干达上述地区,蒿甲醚-苯芴醇疗效低于其他受试联合疗法,需考虑调整一线治疗。
- 对使用蒿甲醚-苯芴醇治疗失败的患儿,可参考药敏结果或换用其他有效联合疗法。
- 监测PfK13突变有助于识别寄生虫清除延迟和潜在耐药风险。
局限性
- 开放标签设计,但研究者和结局评估者设盲。
- 仅纳入6月龄至10岁儿童,结果外推至其他年龄组需谨慎。
- 不同地区使用不同联合疗法比较,非直接头对头比较所有药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-malarial artemisinin-based combination therapies (ACTs) might be losing efficacy in east Africa, with the spread of artemisinin partial resistance and reduced partner drug activity. Our trial aimed to measure the efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine in three sites in Uganda. METHODS: This randomised, open-label, phase 4 clinical trial was carried out at three sites in the Agago, Arua, and Busia districts of Uganda. Children aged 6 months to 10 years with uncomplicated Plasmodium falciparum malaria were randomly assigned to receive either artemether-lumefantrine (20 mg artemether; 120 mg lumefantrine; twice a day for 3 days) in all sites or dihydroartemisinin-piperaquine (40 mg dihydroartemisinin and 320 mg piperaquine, once a day for 3 days) in Agago, artesunate-amodiaquine (25 mg artesunate and 67·5 mg amodiaquine for children <9 kg or 50 mg artesunate and 135 mg amodiaquine for children ≥9 kg, once a day for 3 days) in Busia; and artesunate-pyronaridine (60 mg artesunate and 180 mg pyronaridine for children >15 kg or 20 mg artesunate and 60 mg pyronaridine for children <15 kg, once a day for 3 days) in Arua, with follow-up to 42 days. Participants were not blinded to group assignments; however, investigators and those assessing outcome were masked. The primary outcome was parasitaemia, assessed by microscopy, either uncorrected or PCR-corrected to distinguish recrudescence from new infection. All participants who received the treatment per protocol and were not lost to follow-up were included in the primary outcome. All participants who were randomly allocated to treatment groups were included in the safety analyses. This study is registered with the Pan African Clinical Trials Registry, number PACTR202301796134887, and is complete. FINDINGS: Between Nov 7, 2022, and March 24, 2023, 808 participants (437 [54%] female) were enrolled and assigned to treatment groups; 15 (2%) were lost to follow-up and 793 (98%) completed follow-up. The uncorrected adequate clinical and parasitological response for artemether-lumefantrine was 87 (51·8%; 95% CI 44·0-59·5) of 168 participants in Arua, 88 (51·8%; 44·0-59·4) of 170 and Busia, and 131 (79·4%; 72·3-85·1) of 165 in Agago. This response for artemether-lumefantrine was lower than that of the other ACTs at all sites: 97 (98·0%; 92·2-99·6) of 99 for dihydroartemisinin-piperaquine in Agago, 95 (99·0%; 93·5-99·9) of 96 for artesunate-amodiaquine in Busia, and 73 (73·7%; 63·8-81·8) of 99 for artesunate-pyronaridine in Arua. PCR-corrected 28-day efficacies were 88 (81·5%; 72·6-88·1) of 108 for artemether-lumefantrine and 95 (100%; 95·2-100·0) of 95 for artesunate-amodiaquine in Busia; 131 (97·0%; 92·1-99·0) of 135 for artemether-lumefantrine and 97 (100%; 95·3-100·0) of 97 for dihydroartemisinin-piperaquine in Agago; and 87 (82·1%; 73·2-88·6) of 106 for artemether-lumefantrine and 73 (92·4%; 83·6-96·9) of 79 for artesunate-pyronaridine in Arua. All regimens were well tolerated. The most common adverse events were upper respiratory tract infection, diarrhoea, and anaemia. None of the reported adverse events were attributed to the study drugs. There were two serious adverse events, both cases of severe malaria in Arua, one in each of the treatment groups. Parasite clearance half-lives were prolonged with parasites carrying the PfK13 Cys469Tyr (median 4·2 h; IQR 3·4-4·9) and Ala675Val (4·9 h; 3·4-5·7) mutations compared with wild-type parasites (2·8 h; 2·3-3·6; p<0·0001). INTERPRETATION: Artemether-lumefantrine was associated with a higher risk of recurrent malaria than other antimalarial combinations tested, and K13 mutations were associated with delayed parasite clearance. Changes in first-line therapy for uncomplicated malaria must be considered in response to suboptimal efficacy of artemether-lumefantrine. FUNDING: US President's Malaria Initiative, US Agency for International Development, through the Uganda Malaria Reduction Activity and the National Institutes of Health (AI075045 and AI117001). TRANSLATION: For the Swahili translation of the abstract see Supplementary Materials section.
引用
- Kamya MR, Nankabirwa JI, Ebong C, et al. Efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial. Lancet Infect Dis. 2025. PMID: 40845863. doi:10.1016/S1473-3099(25)00407-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。